BACKGROUND: Hypertrophic cardiomyopathy (HCM) is predominantly caused by a large number of various mutations in the genes encoding sarcomeric proteins. However, two prevalent founder mutations for HCM in the alpha-tropomyosin (TPM1-D175N) and myosin-binding protein C (MYBPC3-Q1061X) genes have previously been identified in eastern Finland. OBJECTIVE: To assess the prevalence of these founder mutations in a large population of patients with HCM from all over Finland. Patients and methods. We screened for two founder mutations (TPM1-D175N and MYBPC3-Q1061X) in 306 unrelated Finnish patients with HCM from the regions covering a population of ∼4,000,000. RESULTS: The TPM1-D175N mutation was found in 20 patients (6.5%) and the MYBPC3-Q1061X in 35 patients (11.4%). Altogether, the two mutations accounted for 17.9% of the HCM cases. In addition, 61 and 59 relatives of the probands were found to be carriers of TPM1-D175N and MYBPC3-Q1061X, respectively. The mutations showed regional clustering. TPM1-D175N was prevalent in central and western Finland, and MYBPC3-Q1061X in central and eastern Finland. CONCLUSION: The TPM1-D175N and MYBPC3-Q1061X mutations account for a substantial part of all HCM cases in the Finnish population, indicating that routine genetic screening of these mutations is warranted in Finnish patients with HCM.
BACKGROUND:Hypertrophic cardiomyopathy (HCM) is predominantly caused by a large number of various mutations in the genes encoding sarcomeric proteins. However, two prevalent founder mutations for HCM in the alpha-tropomyosin (TPM1-D175N) and myosin-binding protein C (MYBPC3-Q1061X) genes have previously been identified in eastern Finland. OBJECTIVE: To assess the prevalence of these founder mutations in a large population of patients with HCM from all over Finland. Patients and methods. We screened for two founder mutations (TPM1-D175N and MYBPC3-Q1061X) in 306 unrelated Finnish patients with HCM from the regions covering a population of ∼4,000,000. RESULTS: The TPM1-D175N mutation was found in 20 patients (6.5%) and the MYBPC3-Q1061X in 35 patients (11.4%). Altogether, the two mutations accounted for 17.9% of the HCM cases. In addition, 61 and 59 relatives of the probands were found to be carriers of TPM1-D175N and MYBPC3-Q1061X, respectively. The mutations showed regional clustering. TPM1-D175N was prevalent in central and western Finland, and MYBPC3-Q1061X in central and eastern Finland. CONCLUSION: The TPM1-D175N and MYBPC3-Q1061X mutations account for a substantial part of all HCM cases in the Finnish population, indicating that routine genetic screening of these mutations is warranted in Finnish patients with HCM.
Authors: Lauri Lehmonen; Mikko Jalanko; Mika Tarkiainen; Touko Kaasalainen; Johanna Kuusisto; Kirsi Lauerma; Sauli Savolainen Journal: BMC Med Imaging Date: 2020-07-01 Impact factor: 1.930
Authors: Sari U M Vanninen; Krista Leivo; Eija H Seppälä; Katriina Aalto-Setälä; Olli Pitkänen; Piia Suursalmi; Antti-Pekka Annala; Ismo Anttila; Tero-Pekka Alastalo; Samuel Myllykangas; Tiina M Heliö; Juha W Koskenvuo Journal: PLoS One Date: 2018-09-20 Impact factor: 3.240
Authors: Mika Tarkiainen; Petri Sipola; Mikko Jalanko; Tiina Heliö; Pertti Jääskeläinen; Kati Kivelä; Mika Laine; Kirsi Lauerma; Johanna Kuusisto Journal: Sci Rep Date: 2019-04-11 Impact factor: 4.379
Authors: Pertti Jääskeläinen; Jagadish Vangipurapu; Joose Raivo; Teemu Kuulasmaa; Tiina Heliö; Katriina Aalto-Setälä; Maija Kaartinen; Erkki Ilveskoski; Sari Vanninen; Liisa Hämäläinen; John Melin; Jorma Kokkonen; Markku S Nieminen; Markku Laakso; Johanna Kuusisto Journal: ESC Heart Fail Date: 2019-02-18
Authors: Benedicte Jørgenrud; Mikko Jalanko; Tiina Heliö; Pertti Jääskeläinen; Mika Laine; Mika Hilvo; Markku S Nieminen; Markku Laakso; Tuulia Hyötyläinen; Matej Orešič; Johanna Kuusisto Journal: PLoS One Date: 2015-08-12 Impact factor: 3.240
Authors: Mika Tarkiainen; Petri Sipola; Mikko Jalanko; Tiina Heliö; Mika Laine; Vesa Järvinen; Kaisu Häyrinen; Kirsi Lauerma; Johanna Kuusisto Journal: J Cardiovasc Magn Reson Date: 2016-06-04 Impact factor: 5.364